<DOC>
	<DOCNO>NCT00838578</DOCNO>
	<brief_summary>The primary objective Phase II portion study ass efficacy KRN330 combination irinotecan first-line adjuvant FOLFOX ( 5-fluorouracil , leucovorin , oxaliplatin ) /CapOx ( capecitabine oxaliplatin ) treatment failure patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase I/II Study KRN330 Plus Irinotecan Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Phase II portion open-label , single arm study . Based result Phase I portion , weekly KRN330 ( 0.5 mg/kg ) biweekly irinotecan ( 180 mg/m2 ) use Phase II portion . To eligible Phase II portion , patient recur progress within 6 month last cycle FOLFOX/CapOx +/- bevacizumab ( first-line adjuvant regimen metastatic colorectal cancer ) . Patients continue treatment disease progression . Per protocol , decision make terminate study base interim analysis result . The Response Rate Phase II meet protocol-specified RR 15 % 0.5 mg/kg KRN330 administer weekly combination irinotecan ( 180 mg/m2 ) biweekly .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antineoplastic Agents , Phytogenic</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<mesh_term>Antimetabolites , Antineoplastic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antimetabolites</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Have histologically confirm colorectal cancer metastatic measurable disease . For Phase II portion : Have recur progress within 6 month last cycle FOLFOX +/ bevacizumab firstline adjuvant regimen metastatic colorectal cancer . Note : Those initiated FOLFOX/CapOx stop oxaliplatin intolerable toxicity also eligible . At least 4 week elapse since last chemotherapy , radiotherapy , immunotherapy , biologic therapy prior enrollment ( except least 6 week case nitrosourea mitomycin ) . Have receive investigational agent within 4 week study entry fully recover adverse event due prior therapy . At least 4 week elapse since major surgery . Have ECOG performance status 0 , 1 , 2 . Have adequate bone marrow organ function Have active , uncontrolled infection . Have know HIV positive status . Have know suspected cerebral metastasis . Have myocardial infarction ( MI ) cerebrovascular accident ( CVA ) within last 6 month ; meet criterion AHA class III IV congestive heart failure ( CHF ) . Have medical condition require chronic use highdose corticosteroid chronic immunosuppressive therapy ( e.g . methotrexate , azathioprine ) . Have history great equal Grade 2 allergic reaction hypersensitivity follow exposure humanize human monoclonal antibody ( chimeric antibody ) . Pregnant breastfeed woman male female patient agree use effective contraceptive method ( ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>KRN330</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Antimetabolites , Antineoplastic</keyword>
	<keyword>Digestive System Neoplasms</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Intestinal Neoplasms</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Gastrointestinal Neoplasms</keyword>
	<keyword>Antineoplastic Agents , Phytogenic</keyword>
	<keyword>Colorectal Neoplasms</keyword>
</DOC>